Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Robert I. Haddad(Georgetown University), Ranee Mehra(University of Maryland, Baltimore), Makoto Tahara(National Cancer Center Hospital East), Shilpa Gupta(Cleveland Clinic), Barbara Burtness(Yale University), Joseph P. Eder(Yale Cancer Center), Lingkang Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jared Lunceford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Răzvan Cristescu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laura Q.M. Chow(The University of Texas at Austin), Andrew Albright(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyunseok Kang(Johns Hopkins University), Kei Muro(Aichi Cancer Center), Robin Mogg(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bhumsuk Keam(Seoul National University), Jared Weiss(Georgetown University), Iris Gluck(Sheba Medical Center), Mark Ayers(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jonathan D. Cheng(Princeton University), Tanguy Y. Seiwert(Georgetown University)
Cited by 96
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k